ロード中...
Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma—experience at two centres
BACKGROUND: Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least on...
保存先:
| 出版年: | J Gastrointest Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212104/ https://ncbi.nlm.nih.gov/pubmed/32399277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2020.03.10 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|